Streetbeat News

Products Services

DBA

NVDA

Agricultural commodity prices, particularly cocoa, have surged to 9-year highs, with cocoa prices increasing by 112% year to date, significantly impacting the Invesco DB Agriculture Fund (DBA) and outperforming stocks like Nvidia Corp. (NVDA). The rise in cocoa costs is attributed to supply disruptions in West Africa, leading to a global cocoa market imbalance and predictions of higher chocolate prices. The International Cocoa Organization predicts a dramatic deficit in the global cocoa market for the 2023/24 season.

Portfolio Pulse from Piero Cingari

March 22, 2024 | 8:26 pm

GOOGL

HAS

Larian Studios, led by Swen Vincke, has decided not to produce any DLC, expansions, or sequels for Baldur's Gate 3, despite its success. At GDC 2024, Vincke expressed the team's lack of enthusiasm for continuing the series and their desire to pursue new projects. He also reflected on the regrettable decision to partner with Google Stadia for the game's announcement, a platform that was shut down in 2023. Hasbro Inc's Wizards of the Coast will continue to support Baldur's Gate 3.

Portfolio Pulse from Franca Quarneti

March 22, 2024 | 8:22 pm

AAPL

A Steve Jobs-autographed business card sold for $181,183 at an auction, setting a new record for the most expensive business card ever sold. The auction featured Apple-related memorabilia, including a rare Apple-1 computer signed by Steve Wozniak and a first-generation sealed iPhone. An Elon Musk-signed SpaceX business card also exceeded expectations, selling for $39,238. The high sale prices reflect the growing demand for memorabilia associated with Jobs and Musk among collectors and investors.

Portfolio Pulse from Chris Katje

March 22, 2024 | 8:19 pm

MASI

Masimo Corporation's Board of Directors has authorized management to evaluate the potential separation of its consumer business, including consumer audio and health products. The company plans to retain its professional healthcare and telehealth products. Joe Kiani is expected to be named Chairman of the newly created company focusing on the consumer segment.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 8:06 pm

IVVD

Invivyd's stock price increased following the FDA's emergency use authorization for PEMGARDA, a pre-exposure prophylaxis for COVID-19. Additionally, the company shared interim exploratory data from its CANOPY clinical trial on VYD222.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 7:56 pm

FLOKIUSD

PEPEUSD

Leshka.eth shared her journey of turning $94 into $1.14 million in 3 months by trading meme coins, emphasizing the importance of community support, influencer endorsements, and strategic buying and selling. Despite the high risk and volatility in meme coin trading, she highlights the potential for significant profits. The meme coin market recently saw a 5.3% drop, but coins like Floki, Pepe, and Dogwifhat have seen substantial gains and entered the $2 billion market cap club.

Portfolio Pulse from Khyathi Dalal

March 22, 2024 | 7:43 pm

UNH

UnitedHealth Group announced that its Relay Exchange will be back online by the weekend of March 23, with third-party documentation. As of March 22, claims totaling over $14B have been staged for processing through the Assurance software. The company plans to engage other submitters and expects to have engaged all submitters by the week of March 25.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 7:17 pm

ESPR

Esperion Therapeutics Inc announced that the determination for its European cardiovascular risk reduction label is expected in Q2 2024. This development could significantly impact the company's market positioning and future revenue streams in Europe.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 7:13 pm

ESPR

The FDA has approved new label expansions for Esperion's NEXLETOL and NEXLIZET, allowing their use in both primary and secondary prevention of cardiovascular events, regardless of statin use. This approval, based on the CLEAR Outcomes trial, significantly increases the treatable population to around 70 million patients in the U.S. Esperion anticipates a positive impact on sales and has prepared by expanding its sales force and promotional efforts. The company also expects a final determination on label expansions in Europe in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 7:12 pm

IVVD

Invivyd announced that its product will be available in the U.S. very soon and expects its current cash reserves to fund operations and capital expenditures into the fourth quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 7:08 pm